TRBJ1-1: A Potential Drug Target for Cancer (G28635)

Target Name: TRBJ1-1

NCBI ID: G28635

TRBJ1-1

Other Name(s): TCRBJ1S1 | TRBJ11 | T cell receptor beta joining 1-1

TRBJ1-1: A Potential Drug Target for Cancer

TRBJ1-1 (Tumor-associated RNA 1) is a protein that is expressed in various types of cancer, including breast, lung, and colorectal cancer. It is a small non-coding RNA molecule that has been shown to play a role in the development and progression of these types of cancer.

Recent studies have identified TRBJ1-1 as a potential drug target for cancer treatment. By inhibiting the activity of TRBJ1-1, researchers have found that they can reduce the growth and spread of cancer cells. Additionally, studies have shown that inhibiting TRBJ1-1 has the potential to be a highly effective way to kill cancer cells that have become resistant to traditional cancer treatments.

One of the reasons why TRBJ1-1 is considered a drug target is because it is expressed in various types of cancer cells, including cancer stem cells. This means that targeting TRBJ1-1 could potentially be a way to treat cancer that has spread to the stem cells, rather than the main tumor cells.

Another potential reason why TRBJ1-1 is a drug target is because it is involved in the development of cancer-inviting immune responses. When cancer cells evade the immune system, they can continue to grow and spread. By targeting TRBJ1-1, researchers have found that they can stimulate an immune response against cancer cells, which could potentially help to kill them.

In addition to its potential as a drug target, TRBJ1-1 is also a potential biomarker for cancer. By measuring the levels of TRBJ1-1 in cancer cells, researchers have found that higher levels of TRBJ1-1 are associated with the development and progression of cancer. This could potentially be used as a diagnostic tool for cancer, and could also be used to track the effectiveness of cancer treatments.

Overall, TRBJ1-1 is a protein that has the potential to be a drug target for cancer treatment. By inhibiting the activity of TRBJ1-1, researchers have found that they can reduce the growth and spread of cancer cells and stimulate an immune response against cancer cells. Additionally, TRBJ1-1 is also a potential biomarker for cancer, which could be used as a diagnostic tool and to track the effectiveness of cancer treatments. Further research is needed to fully understand the potential of TRBJ1-1 as a drug target and biomarker for cancer treatment.

Protein Name: T Cell Receptor Beta Joining 1-1

Functions: J region of the variable domain of T cell receptor (TR) beta chain that participates in the antigen recognition (PubMed:24600447). Alpha-beta T cell receptors are antigen specific receptors which are essential to the immune response and are present on the cell surface of T lymphocytes. Recognize peptide-major histocompatibility (MH) (pMH) complexes that are displayed by antigen presenting cells (APC), a prerequisite for efficient T cell adaptive immunity against pathogens (PubMed:25493333). Binding of alpha-beta TR to pMH complex initiates TR-CD3 clustering on the cell surface and intracellular activation of LCK that phosphorylates the ITAM motifs of CD3G, CD3D, CD3E and CD247 enabling the recruitment of ZAP70. In turn ZAP70 phosphorylates LAT, which recruits numerous signaling molecules to form the LAT signalosome. The LAT signalosome propagates signal branching to three major signaling pathways, the calcium, the mitogen-activated protein kinase (MAPK) kinase and the nuclear factor NF-kappa-B (NF-kB) pathways, leading to the mobilization of transcription factors that are critical for gene expression and essential for T cell growth and differentiation (PubMed:23524462). The T cell repertoire is generated in the thymus, by V-(D)-J rearrangement. This repertoire is then shaped by intrathymic selection events to generate a peripheral T cell pool of self-MH restricted, non-autoaggressive T cells. Post-thymic interaction of alpha-beta TR with the pMH complexes shapes TR structural and functional avidity (PubMed:15040585)

The "TRBJ1-1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TRBJ1-1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets